Sosei acquires Heptares Therapeutics for up to $400 million

23 February 2015

Japanese drugmaker Sosei Group (TYO: 4565) says it has acquired Heptares Therapeutics, a clinical-stage private UK-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors (GPCRs).

According to the Japanese firm, the combination will create a leading global biopharmaceutical group with:

sustainable, proven and highly successful drug discovery and clinical development capabilities for generating innovative medicines;
a broad and balanced pipeline with strong growth prospects, including products with blockbuster potential;
access to global pharmaceutical markets;
regulatory expertise across the European Union, USA and Japan; and
a significant cash balance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK